Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 703

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 703
---

“Company”) and Seller. Capitalized terms used but not defined herein have the meanings set forth in the Agreement. The Agreement provides, among other things, for the sale of one hundred percent (100%) of the issued and outstanding capital
stock of the Company (the “Sale Transaction”) upon the terms and subject to the conditions set forth in the Agreement, in exchange for aggregate consideration of $100,000,000 on a cash free, debt free basis (the “Consideration”).
The Consideration is subject to certain adjustments set forth in the Agreement; we express no opinion as to any such adjustments. The terms and conditions of the Sale Transaction are more fully set forth in the Agreement.

We have been engaged by Seller to act as its financial advisor in connection with the Sale Transaction and we will receive a fee from Seller for providing
such services, a portion of which is payable upon delivery of this opinion and the remaining portion of which is payable upon the closing of the transaction. In addition, Seller has agreed to reimburse certain of our expenses arising, and indemnify
us against certain liabilities that may arise, out of our engagement.

Leerink Partners LLC is a full-service securities firm engaged in securities
trading and brokerage activities as well as investment banking and financial advisory services. In addition to our services in connection with the Sale Transaction, we are currently serving as financial advisor to Seller in connection with its entry
into a license agreement with WuXi Biologics (Shanghai FX) Co., Ltd and will receive a fee for such services. In the ordinary course of business, we and our affiliates may in the future provide investment banking services to Seller, Buyer or their
respective affiliates and would expect to receive customary fees for the rendering of such services. In the ordinary course of our business, we or our affiliates have in the past and may in the future hold positions, for our own account or the
accounts of our customers, in equity, debt or other securities of Seller, Buyer or their respective affiliates.

Consistent with applicable legal and
regulatory requirements, we have adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations
and/or publish research reports with respect to Seller, Buyer and the Sale Transaction and other participants in the Sale Transaction that differ from the views of our investment banking personnel.

In connection with this opinion, we have reviewed, among other things: (i) a draft of the Agreement,